Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (8)	12/14/2000 12:36:43 AM
From: Spekulatius	Read Replies (1) \| Respond to of 78

The NDA application is certainly a milestone for PRCS. I am impressed by the business acumen of PRCS management. Keeping half of the Abarelix profits, AMGN pays for the first 175M$ in development expenses,plus a credit line of 150M$. Together with their cash almost 300M$ in funding available. This is certainly not a nickel and a dime business plan. If their LEAP drug development platform is really as good as Gefter says it is, this should be a very good growth play for years to come.